News|Articles|November 18, 2026

IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New Drugs

Fact checked by: Ashley Gallagher, MA
Listen
0:00 / 0:00

Key Takeaways

  • Late specialist presentation is driven by overlooked proteinuria, missed follow-up of abnormal urinalyses, variable biopsy access, and limited primary care engagement among young adults.
  • Newer therapies such as SGLT2 inhibitors, atrasentan, and atacicept elevate the urgency of earlier detection to prevent irreversible nephron loss.
SHOW MORE

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

Finding rare glomerular diseases earlier may depend less on new software than primary care physicians who can recognize the early signs and refer patients to specialists sooner. At a Population Health Roundtable hosted by The American Journal of Managed Care® in San Francisco, California, experts said new therapies for immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS) raise the stakes for catching disease before kidney damage becomes irreversible.

The discussion with 9 clinicians and health system leaders was moderated by Raymond Hsu, MD, MAS, University of California, San Francisco. Some participants in this discussion asked their comments not to be attributed directly to them, so their comments are attributed generally.

Why Patients With Rare Kidney Diseases Reach Specialists Late

Participants

  • Raymond Hsu, MD, MAS, University of California, San Francisco (moderator)
  • Harini Sarathy, MBBS, MHS, University of California, San Francisco
  • Puneet Sood, MD, MPH, University of California, San Francisco
  • Sijie Zheng, MD, PhD, Kaiser Permanente
  • Jane Tan, MD, PhD, Stanford
  • Paul Grimm, MD, Stanford
  • Luis Alvarez, MD, PhD, Palo Alto Medical Foundation/Sutter Health

Faculty described late recognition as the central problem. One participant said proteinuria at diagnosis of IgA nephropathy ranged from about 600 mg in one Northern California community to about 3000 mg in another. Participants linked the delay to uneven biopsy access, young adults with no primary care contact, and abnormal urine findings that get explained away and never rechecked.

Paul Grimm, MD, of Stanford, said he has seen charts in which menstrual bleeding was blamed for protein in the urine for a year before a patient arrived with elevated creatinine. He noted that the American Academy of Pediatrics dropped screening urinalysis from its health supervision guidelines in 2007 on cost-benefit grounds, at a time when conditions such as Alport syndrome and IgA nephropathy had no specific therapies and there was little evidence that early intervention changed outcomes. That calculus may no longer hold, he said, given newer options that reduce proteinuria and preserve GFR, including SGLT2 inhibitors, atrasentan (Vanrafia; Novartis Pharmaceuticals), and atacicept (Trutakna; Vera Therapeutics).

“Maybe advocating for bringing back screening urinalysis or risk-based screening urinalysis would be a way to get these people in the system earlier,” Grimm said.

What Helps Primary Care Recognize and Refer?

One health system spent heavily on electronic health record software to detect proteinuria, only to find that primary care physicians would not use a tool requiring 2 clicks. “We started doing grand rounds in internal medicine to teach people. And that was actually more effective than the millions of dollars we spent on software,” said a health-system nephrologist.

An electronic consult service at San Francisco General allows specialists to triage the early referrals that growing primary care screening for diabetes and hypertension is producing, said Harini Sarathy, MBBS, MHS, of the University of California, San Francisco (UCSF). There is also a display on the electronic record’s main screen of the kidney failure risk equation that has helped primary care think about when to refer and may have increased referrals to chronic kidney disease care, though she was unsure how it affects rare kidney diseases.

How Are Teams Taking Access Work Off Physicians?

At UCSF, a specialty pharmacy team handles prior authorizations, appeals, and copay assistance while an embedded clinic pharmacist helps patients navigate access. One health system hands off to a dedicated team once a treatment decision is made, covering drug acquisition, delivery, and patient education. Another relies on a glomerular disease pharmacist to order medications and a weekly case conference for hard-to-manage patients.

However, gaps remain, such as when drugs ship from outside limited-distribution pharmacies and clinics lose sight of laboratory monitoring and therapy gaps, participants said, and several clinics lack social workers. “I don’t know what system, but we need to have extra help where physicians are not responsible for constantly following up,” Sarathy said.

Grimm said about 40% of his pediatric patients travel from the Central Valley, and families often must weigh missed work against clinic visits. “They have to make a choice: do I take my kid in for a doctor’s visit, or do I go and make some money to keep a roof over our head?” he said. His network’s year-long navigator program assigns a staff member to accompany high-need families to every appointment.

How Pathways Can Keep Pace With Evidence

Written protocols age quickly as therapies change, requiring rapid reviews of updates to the organization’s treatment guidelines. One transplant program wrote step-by-step protocols for recurrent IgA nephropathy, FSGS, and C3 glomerulopathy, where previously nothing was protocolized. “We wrote our first IgA guideline about a year and a half ago. Since then, we have actually revised it 3 times now,” said a transplant nephrologist.

One participant suggested pairing local guidelines with scheduled reviews because national guidance can lag new approvals and noted that some payers allow only one FSGS treatment, limiting options. Another participant called a physician-to-physician warm handoff key when patients move from pediatric to adult care, the easiest where systems share an electronic record.

A Key Change to Improve Outcomes

Faculty did not name a single fix, but coordination was a common thread. Sarathy noted that she would like more help to get patients through screening and treatment processes. Similarly, another participant said they would like a social worker for the clinic.

“I think that the word I loved the most that was spoken by multiple people today is ‘optimism,’ that we finally have approved therapies for these rare glomerular diseases, that things are really changing,” Hsu concluded.


Related to this article